GI
HZNP

GAMCO Investors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

GAMCO Investors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-49,265
Closed -$5.7M – 888
2023
Q3 		$5.7M Buy
49,265
+15,215
+45% +$1.63M 0.07% 301
2023
Q2 		$3.5M Buy
34,050
+2,050
+6% +$216K 0.04% 390
2023
Q1 		$3.49M Buy
32,000
+8,650
+37% +$956K 0.04% 385
2022
Q4 		$2.66M Buy
+23,350
New +$1.94M 0.03% 420

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

GAMCO Investors's HZNP Position: Q4 2023 in Review

GAMCO Investors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 49,265 shares — an estimated $5.7M sold.

GAMCO Investors first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $5.7M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • GAMCO Investors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • GAMCO Investors sold 49,265 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $5.7M.
  • GAMCO Investors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • GAMCO Investors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.7M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on GAMCO Investors's 13F filing for Q4 2023, filed 14 Feb 2024.